GSKGlaxoSmithKlineSigning up patients
A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC)
Neoplasms, Endometrial
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 30 (planned)
- Started
- Nov 27, 2025
- Main results expected
- Mar 31, 2030
- Fully finished
- Mar 31, 2030
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Durable Response Rate for 12 months (DRR12) assessed by Blinded Independent Central Review (BICR)
Measured over: Up to approximately 148 weeks
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07108270 · record last updated 2025-12-22 · checked 2026-11-09 15:47 UTC